BiotechTube

Aztreonam lysine

ApprovedTerminated
3 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bronchiectasis Adult

Conditions

Bronchiectasis Adult

Trial Timeline

Oct 19, 2019 → Mar 4, 2025

NCT ID
NCT03696290

About Aztreonam lysine

Aztreonam lysine is a approved stage product being developed by Gilead Sciences for Bronchiectasis Adult. The current trial status is terminated. This product is registered under clinical trial identifier NCT03696290. Target conditions include Bronchiectasis Adult.

What happened to similar drugs?

0 of 9 similar drugs in Bronchiectasis Adult were approved

Approved (0) Terminated (1) Active (8)
❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
🔄Brensocatib 10 mg + Brensocatib 25 mg + PlaceboInsmedPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00989807Pre-clinicalCompleted
NCT03696290ApprovedTerminated

Competing Products

20 competing products in Bronchiectasis Adult

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD9668 + PlaceboAstraZenecaPhase 2
35
AZD5069 + PlaceboAstraZenecaPhase 2
35
AZD0292AstraZenecaPhase 2
42
TIP + TIP and placebo + PlaceboNovartisPhase 2
35
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
40
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
40
QBW251 + PlaceboNovartisPhase 2
27
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
AZLIGilead SciencesPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
35
CSL787 + PlaceboCSLPhase 1
29
CSL787 + PlaceboCSLPhase 2
42
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
47
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
35
Group A + Group BBayerPre-clinical
23
BAY85-8501 + PlaceboBayerPhase 2
32